1. Home
  2. WWR vs XBIT Comparison

WWR vs XBIT Comparison

Compare WWR & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.52

Market Cap

68.8M

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.16

Market Cap

66.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
XBIT
Founded
1977
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Pharmaceuticals and Biotechnology
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
66.8M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
WWR
XBIT
Price
$0.52
$2.16
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $1.92
N/A
AVG Volume (30 Days)
★ 686.5K
44.1K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.38
$2.09
52 Week High
$3.75
$3.44

Technical Indicators

Market Signals
Indicator
WWR
XBIT
Relative Strength Index (RSI) 43.84 41.45
Support Level $0.48 $2.16
Resistance Level $0.62 $2.48
Average True Range (ATR) 0.03 0.04
MACD -0.01 0.00
Stochastic Oscillator 19.40 33.33

Price Performance

Historical Comparison
WWR
XBIT

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: